The most common gastrointestinal adverse events were nausea ( 61 [ 20 % ] in dulaglutide group vs 54 [ 18 % ] in liraglutide group ) , diarrhoea ( 36 [ 12 % ] vs 36 [ 12 % ] ) , dyspepsia ( 24 [ 8 % ] vs 18 [ 6 % ] ) , and vomiting ( 21 [ 7 % ] vs 25 [ 8 % ] ) , with similar rates of study or study drug discontinuation because of adverse events between the two groups ( 18 [ 6 % ] in each group ) .